Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Hemispherx Biopharma Inc. Stories

2013-01-17 20:22:34

SAN DIEGO and PHILADELPHIA, Jan. 17, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that purchasers of Hemispherx Biopharma, Inc. (NYSE: HEB) ("Hemispherx" or the "Company") have filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania. The complaint alleges the Company and certain of its officers and directors violated the Securities Exchange Act of 1934 between March 19, 2012 and December 17, 2012 (the "Class Period")....

2013-01-04 08:24:18

HONG KONG, Jan. 4, 2013 /PRNewswire/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and equity research for the following companies: Vringo (AMEX:VRNG), Longwei Petroleum (AMEX:LPH), Rentech (AMEX:RTK), Vanguard (ARCA:VOO), Hemispherx BioPharma (AMEX:HEB), and World Moto (OTC:FARE). (Logo: http://photos.prnewswire.com/prnh/20121105/HK06856LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.) Report...

2012-12-28 20:20:30

NEW YORK, Dec. 28, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (NYSE: HEB). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO) The investigation focuses on whether the Company and its executives violated federal securities laws by issuing a series of materially false and misleading statements regarding the efficacy of Hemispherx's...

2012-12-19 08:25:26

NEW YORK, Dec. 19, 2012 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (NYSE MKT: HEB). The investigation focuses on whether the Company and its executives violated federal securities laws. On December 18, 2012, shares of Hemispherx fell over 27 cents or 42.86% to close at $0.368 after a government report questioned...

2011-04-14 08:30:00

TSX Venture: QPT EDMONTON, April 14 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial. Under the...

2010-11-16 07:00:00

PHILADELPHIA, Nov. 16, 2010 /PRNewswire/ -- Berger & Montague, P.C. and Brower Piven, A Professional Corporation, Co-Lead Counsel for Lead Plaintiff and the Class in the Hemispherx Biopharma, Inc. securities class-action suit, announced the following: IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA ---------------------------: IN RE HEMISPHERX : BIOPHARMA, INC. LITIGATION : CIVIL ACTION NO....

2010-04-01 09:00:00

RESEARCH TRIANGLE PARK, N.C., April 1 /PRNewswire-FirstCall/ -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders, and Max Neeman International is one of the leading and largest clinical research organizations ("CROs") in India. They jointly announced today a collaborative clinical research effort for one of Hemispherx' flagship products,...

2010-01-05 07:05:00

PHILADELPHIA, Jan. 5 /PRNewswire/ -- The law firm of Berger & Montague, P.C. has filed a class action in the U.S. District Court for the Eastern District of Pennsylvania that expands the proposed class period to include all purchasers of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (Amex: HEB) securities between February 18, 2009 and December 1, 2009, inclusive (the "Class Period"). The class period in the earlier lawsuit against the Company ended on October 30, 2009....

2009-12-08 15:00:00

MEDIA, Pa., Dec. 8 /PRNewswire/ -- Shepherd, Finkelman, Miller & Shah, LLP (http://www.sfmslaw.com; e-mail: jmiller@sfmslaw.com), a law firm with offices in California, Connecticut, Florida, New Jersey, Pennsylvania and Wisconsin, has filed a lawsuit seeking class action status in the United States District Court for the Eastern District of Pennsylvania against Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (Amex: HEB) and the Company's CEO, William A. Carter, M.D., on...

2009-05-27 07:00:00

CLINTON, N.J., May 27 /PRNewswire/ -- The Sage Group, a privately held international health care consulting group, announced today that HemispherX Biopharma has expanded the mandate for The Sage Group to include, in addition to the strategic partnering efforts related to Ampligen (an experimental immunotherapeutic) for Chronic Fatigue Syndrome*, additional partnering efforts related to Ampligen's use to increase the effectiveness of preventative pandemic flu vaccines and the additional role...